hbp caso clínico

8/18/2019 HBP caso clínico

1/24

“UNIVERSIDAD NACIONAL DE SANCRISTÓBAL DE HUAMANGA”

FACULTAD DE CIENCIAS BIOLÓGICASESCUELA DE FORMACIÓN PROFESIONAL

DE FARMACIA Y BIOQUÍMICA

SEGUIMIENTO FARMACOTERAPEUTICO ENPACIENTES CON HBP

AREA: FARMACOTERAPIA CF-544

DOCENTE: MG. QF. CASTILLO TORRES NANCY

INTEGRANTES:

ARANGO PALOMINO, MADELEINE E.

BARBARAN VILCATOMA, STEPHANY M. JANAMPA ONCEBAY, EDITH GLORIA SANTIAGO CHAVEZ, DANIEL.

DIA DE PRACTICA: MIERCOLES 2:00 4:00 !"

AYACUCHO- PERÚ

202

RACTICA Nº 8


2/24

SEGUIMIENTO FARMACOTERA EUTICO EN ACIENTES

CON HB

I. Objetivos:

#$%&%'() &( "*$++&+( * S*/%"%*$+1()"(+$*)(!3/$%+ SFT * DADER * *& *6())+&&+ 7 )*6+&/%8 * /

(6+ &%+. I*$%9() &+6 R*6/&$(+6 N*($%+6 * &( M*%(%8 RNM +"+

EFECTOS * *& (6+ &%+. I*$%9() &+6 P)+;&*"(6 R*&(%+(+ + &+6 M*%("*$+6 PRM

+"+ CA#SANTES * &+6 RNM * *& (6+ &%+.

II. Intro!""i#n:

L(


3/24

III. C$so C%&ni"o:

D!"#$%%'( ) *(+!#!,!(+!" ,! #*".

A(+!#!,!(+!" &!$".(*!"

V()8 * (>+6, 1/"(+) * 0 !(?/*$*6(>+ 7 6% +$)+6


4/24

*+&/%8. R*9*)* *@!*$+)(%8 !/)/&*$( * +&+) *)+6( 7 +&+) * *&

!*


5/24

I'. RESU(TA)OS

*.+ OFERTA )E( SER'ICIO


6/24

S). B/*+6 (6 $)(6 &( *(&/(%8 ?/* 6* &*


7/24

H*/*(*OCUPACIÓN: EDAD: => *?." SEO M FPESO: TALLA: IMC:23-HISTORIA DE SALUD233 ANTECEDENTES PATOLOGICOSIMAACVICC

DIABETES T%&. IIENF. RENALOBESIDAD HBP

T$./4."%" 1!(."*&$.5(,*C.%+%"&"!,./!/4$*(."*

OTROSHTA $*,. IIEPOCS4.4"+$##%.(%(+!"+%(*

232 PROBLEMAS DE SALUDSNC AP3

LOCOMOTORS3 DIGESTIVO METABOLICAS

.$+62."()*+6.6/*>+4.*6(*%"%*$

+5.%6%+ ;+))+6(.!*)%( *(!*$%$+.+&+) * (;*'(

.*;%&%("/6/&()K. D+&+)*6()$%/&()*6

0.(&(";)*6.+&+))%%*' * /*&&+

2. D+&+) 7+ ()+) **6$+"(+. N(/6*(6 7+8"%$+6

4. D%())*(65. E6$)*>%"%*$+. S*?/*( ;/(&

. H%!+($)*%(. H%!+!+$(6*"%(K. H%!*)&%*"%(20. H%!*)(&*"%(

2.H%!*)+&*6$*)+&*"%(22. E*"(2. H%!*)!+$(6*"%(

S3CARDIOVASCULAR

PIEL OTROS OTROS

24. P(&!%$(%+*625.$(?/%()%(2. H%!+$*6%8

2. A))%$"%(62. A%(2K.;)(%()%(0. H%!+$*6%8+)$.

.E)/!%+*6/$=*(6

2. P)/)%$+.R/;*1(%8

4. B)++*6!(6"+5. D%6!*!6%(. A%+**"(

. N*/$)+!*%(. P)+$*%/)%(K. L*/+!*%(40. F($%(

4. I"!+$*%(42. A6$*%( @3 FIEBRE@@3 SUDORACIÓN@3 ESCALOFRÍOS

233FUNCIONES VITALESFC: FR: T: PA:23@3HABITOS DE CONSUMOALCOHOLNOT%&.E1!(+* - 1*".,8* . /6"1*".",8*

CIGARRILLOSNOE*$/(& (*$%&&(( (*$%&&(( ,! #*!+%*,8*

CAF NO T%!+E*$/(& 2 $('(( * $('(6(

TENOE*$/(& $('((2 $('(( * 2 $('(6(

233 HABITOS ALIMENTICIOS YO DIETETICOSSAL EN LADIETA

ALIMENTOSCONS#ME

H%!+68%(N+)"+68%(H%!*)68%(

A%%+( +"%(6

C()*6 )+(6P*6(+V*)/)(6

F)/$(6 + +6/"*

P(6$(6H()%(6D/&*6

F)%$/)(623


8/24

23=3 PRUEBAS DE LABORATORIOP$!4* R*6/&$(+ F*3DIAGNOSTICON!/.(%*J EPOC "!1!$*J HTAJ DM IIJ HBPJ23K3 MEDICOS TRATANTES:Q3F3 RESPONSABLE:

E(+$!1%"+* 5*$/*#7+%#*: PROBLEMAS DE SALUD FECHA: 22 DE NOVIEMBRE DEL 202N; 00H.*: 02

P$.4!/* ,! "*, : HTA: !"+*,%. 2I(%#%.: H*#! 0 *?."E &*#%!(+! 5! ,%*(."+%#*,. ,! HTA *#! 0*?."J &*$* . #* !"+6 "%%!(,. ( +$*+*/%!(+.

,! I4!$"*$+6( 00/ 0- 03

P$.4!/* ,! "*, 2:PROSTATA HBPI(%#%.: (. %(,%#*P(%*$* $%** HBP + / )

&**, *6$= 6%*+ $)($(("%+=%+6 * +"!)%"%+

P$.4!/* ,! "*, : NEUMONIAI(%#%.: (. %(,%#*E &*#%!(+! $!9!$! +!(!$ 9!4$!J !&!#+.$*#%'(&$!(+* ,! #..$ 1!$,."*J !"#*.5$8." )",.$*#%'( &*$* #* !"+6 "%!(,. +$*+*,. #.(L!1..*#%(. IV 00/ #2@J #*/4%*(,. *

+!$#!$ ,8* * 18* .$* ) 9(*/!(+! *"+*(,. *,."%" &.$ IRC3

P$.4!/* ,! "*, @: DIAI(%#%.: + %%(P(%*$* $%** DMII !()( /(+ G&%"*!%)%( 2" - 4

P$.4!/* ,! "*, : I(%#%.: EPOC "!1!$*P*#%!(+! &$!"!(+* EPOC SEVERA

O+$* %(5.$/*#%'( $!!1*(+! *!$%*"J %(+!$1!(#%.(!" %$$%#*"J .+$." *(+• P*#%!(+! 5/*,.$ >0 &*!+!" * *?.•

I(5.$/*#%'( 46"%#* * .4+!(!$ ." &$.4!/*" ,! "*, P3S3:• P$!.#&*#%'( ) !&!#+*+%1*" ,! &*#%!(+! $!"&!#+. * P3S3J• &!$#!%'( ".4$! ! #.(+$. ,! P3S3 "8(+./*"J "%(."J &*$6/!+$." #*(+%

!1.#%'( ,! * !(5!$/!,*,J %(+!$&$!+*#%'( ,! ." &*$6/!+$." #*(+%9#*


9/24

,.+ ESTA)O )E SITUACION

-.+ FASE )E ESTU)IO

-.*. $to%o&$s

PATOLOGIA

DEFINICION

HIPERPLASIA

BENIGNAPROSTATICA HBP

L( HBP +6%6$*, !+) / &(+, * *& (/"*$+ *& $("(>+ * &( !)+;6$)/%8 !)+)*6%( *& /+ /)%()%+ +"!+*$* *6$=$%+ 7 !+) +$)*& "6/&+ *$)/6+) +"!+*$* %="%+. S/ !)*(&*%( (/"*$()%$*)%+6


10/24

(+)"(& 7 &( $+6 )8%(. A "*%( ?/* &( *1*)"*( *"!*+)(, !/**+$%%((6 +"+ 6/;%) /+6 /($+6 *6(&+*6 + &&*() /( "(&*$(.

DM +%&. 2

L( %(;*$*6 $%!+ 2 *6 /( *1*)"*( ?/* /)( $+( &( %( )8%(('() &/+6( * &( 6()*. C+ 1)*/*%(, &(6 !*)6+(6 + %(;*

(&/+ (& !)%%!%+ 7 *6 !+6%;&* ?/* + $*( 6$+"(6 /)($* "/8, &( !%*& /1)*/*$*6 + 6(( &*$("*$*, 1($%(, + *6 "*%(+ !+) +6 *@!)*+"%%+ *$*)+$8@%+ &( !)%"*)( 7 %#( *' &*6%+(( &( !()* %$*6$%(&, &( "/+6( 6* "/*6$)(


11/24

+ (&(";)*6, "(& (&%*$+, S/6*!$%;%&%( ( +,


12/24

T*)('+6%( $%**(*"=6 / *1*$+


13/24

-.-. RAMs

FRMACO RAMSIRBESARTAN H%!*)!+$(6*"%( K, "()*+ 0, #RI K,

H%!+$*6%8 +)$+6$=$%( 5, 1($%( 4, %())*( ,

%6!*!6%( 2.ALBUTEROL T*";&+) 20, *)%+6%6"+ * 2- (>+6 &+6 %>+6 5,

=/6*(6 0, 1%*;)* ,-K, ;)++*6!(6"+ ,8"%$+6 , +&+) * (;*'( 4-, "()*+ -, $+65, )*(%+*6 (&3)%(6 4, +$%$%6 "*%( ,,*!%6$(@%6 * %>+6 , (/"*$+ *& (!*$%$+ , #TI, ;+( 6*( , *)/$+6 + ($/&*%( ,(/"*$+ * &( 6/+)(%8 , *6(&+1)+6 2,%6!*!6%( -2,


14/24

)*6!%)($+)%+ 6/!*)%+), +&+) (;+"%(&, )*/)%$(%8=%(, *6$)*>%"%*$+, %())*(, 8"%$+6, ($/&*%(,=/6*(, *)/!%8, (&$*)(%8 *& /6$+, F)*/*%( N+D*9%+: 1)($/)( * %"%*$+ , "()*+6 , %6!*!6%( 2, 8"%$+62, )(6< 2, !)/)%$+ , +&+) * *& !*


15/24

=*) * "("( "(6/&%+, **"( &+(&%'(+INSULINANPH

H%!+&/*"%(, )*6%6$*%( ( &( %6/&%(, &%!+%6$)+9(,&%!+


16/24

-.4. Inter$""iones

F3

PRECIPITANTE

F3 OBETO MECANISMO DE INTERACCION

OMEPRAOL CLOPIDOGREL O"*!)('+& %6"%/7* &+6 *1*$+6 * &+!%+)*& (& (1*$() *& "*$(;+&%6"+ * &(6

*'%"(6


17/24

LEVOFLOACI

NA

GLIMEPIRIDA L*++@(%( (/"*$( &+6 *1*$+6 * &%"*!%)%( !+) 6%*)%6"+ 1()"(+%="%+.

A"%%6$)(%8 * ?/%+&+(6 + ($%;%8$%+6 !/** )*6/&$() *


18/24

ALBUTEROL FUROSEMIDA M*(%6"+: 6%*)%6"+ 1()"(+%="%+. I$*)(%8 "*+) + + 6%%9($%(. L(


19/24

'. )is"!si#n:

'I. Con"%!siones:

S* /$%&%'8 &( "*$++&+( * S*/%"%*$+ 1()"(+$*)(!3/$%+ SFT * DADER

* *& *6())+&&+ 7 )*6+&/%8 * / (6+ &%+. S* %*$%98 &+6 R*6/&$(+6 N*($%+6 * &( M*%(%8 RNM +"+ EFECTOS

* *& (6+ &%+. S* %*$%98 &+6 P)+;&*"(6 R*&(%+(+ + &+6 M*%("*$+6 PRM +"+

CA#SANTES * &+6 RNM * *& (6+ &%+.

'II. C!estion$rio:

3 E( * 5*"! ,! %(+!$1!(#%'( ,! 5*$/*#7+%#. ! +$*+*/%!(+. (.5*$/*#.+!$*&7+%#. $!#./!(,*$8*3

L+6 +;*$%+6 *& $)($("%*$+ 6+ %6"%/%) &+6 6$+"(6, "*+)() &((&%( * %( 7 *%$() &( (!()%%8 * +"!&%(%+*6. E !(%*$*6 +

6%$+"($+&+( &**-"+*)(( 7 !+( (1*$(%8 * 6/ (&%( * %( 6*

)*+"%*( /( +/$( *@!*$($* ?/* %&/7* %1+)"(%8 (& !(%*$*

6+;)* &( ($/)(&*'( ;((& * &( 6%$+"($+&+(, +6*+6 6+;)* *& *6$%&+ *

%( 7 / 6*/%"%*$+ )/$%()%+. E (&/+6 !(%*$*6 &+6 6$+"(6 !/**

"*+)() *6!+$=*("*$*, "%*$)(6 ?/* * +$)+6 6* "($%** *6$(;&*6

/)($* "/+6. #( )*%6%8 "+6$)8 ?/* ( &+ &()+ * / !*)%++ *6*/%"%*$+ * 2, ( 5 (>+6, / * &+6


20/24

P+) +$)+ &(+ *@%6$* *& $)($("%*$+ ?/%))%+ *6$+ 6* ( * &+6 (6+6 * &(

*@%6$*%( * 6$+"(6 )*1)($()%+6 ( $)($("%*$+ 1()"(+&8%+, (6 +"+

&( !)*6*%( * +"!&%(%+*6 %"!+)$($*6 +"+ &( )*$*%8 /)%()%(

!*)"(*$* + )*/))*$*,


21/24

3 P*"/! *" RAM" ! %(+!$*##%.(!" !( (* +*4* %(#)* !/!#*(%"/. ,! %(+!$*##%'(J ! %(,%! #* !" ! /!,%#*/!(+..4!+. ) &$!#%&%+*(+! ,! ." /!,%#*/!(+." !(#.(+$*,." !( !#*". #8(%#.J #./. ." #*"*(+!" PRM ,! ." RAM"J %(#)*."!( * F*"! ,! E1**#%'(3

F3

PRECIPITANTE

F3 OBETO MECANISMO DE INTERACCION

OMEPRAOL CLOPIDOGREL O"*!)('+& %6"%/7* &+6 *1*$+6 *

&+!%+)*& (& (1*$() *& "*$(;+&%6"+ * &(6

*'%"(6


22/24

PREDNISOLO

NA

CLOPIDOGREL P)*%6+&+( %6"%/%)= *& %*& + *& *1*$+

* &+!%+)*& (& (1*$()


23/24

PREDNISOLO

NA

LEVOFLOACI

NO

L( ("%%6$)(%8 +/$( * &(6 ?/%+&+(6

7 &+6 +)$%+6$*)+%*6 !/** (/"*$() *&

)%*6+ * )+$/)( *& $*8IRBESARTN ALBUTEROL D%6"%/7* *& !+$(6%+ 63)%+. E1*$+ * &(

%$*)(%8 + *6 &()(, $*( /%(+.FUROSEMIDA IRBESARTN S* )*/* *& !+$(6%+ 63)%+. E1*$+ * &(

%$*)(%8 + *6 &()(, $*( /%(+.

S%%9($%+ - %%&() * *)(ALBUTEROL FUROSEMIDA M*(%6"+: 6%*)%6"+ 1()"(+%="%+.

I$*)(%8 "*+) + + 6%%9($%(. L(


24/24

* %%*";)* *& 202, 20: X-. D%6!+%;&* *:

hbp caso clínico

Documents